Literature DB >> 19720094

Efficient replication systems for hepatitis C virus using a new human hepatoma cell line.

Nobuyuki Kato1, Kyoko Mori, Ken-ichi Abe, Hiromichi Dansako, Misao Kuroki, Yasuo Ariumi, Takaji Wakita, Masanori Ikeda.   

Abstract

Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a serious global health problem. Cell culture-based persistent HCV RNA replication systems and infectious HCV production systems are widely used in HCV research. However, persistent HCV production systems have been developed only for HuH-7 hepatoma cells. Here we found a new human hepatoma cell line, Li23, that enables persistent HCV production and anti-HCV reagent assay. Li23's cDNA expression profile differed from HuH-7's, although the two cells had similar liver-specific expression profiles. We used HCV RNA with a specific combination of adaptive mutations to develop an HCV replicon system and genome-length HCV RNA replicating systems including a reporter assay system. Finally, Li23-derived cells persistently produced infectious virus of an HCV strain. Li23-derived cells are potentially useful for understanding the HCV life cycle and for finding antiviral targets.

Entities:  

Mesh:

Year:  2009        PMID: 19720094     DOI: 10.1016/j.virusres.2009.08.006

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  14 in total

1.  Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122.

Authors:  Hiroto Kambara; Takasuke Fukuhara; Mai Shiokawa; Chikako Ono; Yuri Ohara; Wataru Kamitani; Yoshiharu Matsuura
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

2.  Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.

Authors:  Kyoko Mori; Youki Ueda; Yasuo Ariumi; Hiromichi Dansako; Masanori Ikeda; Nobuyuki Kato
Journal:  Virus Genes       Date:  2012-01-18       Impact factor: 2.332

3.  Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities.

Authors:  Weilin Gu; Youki Ueda; Hiromichi Dansako; Shinya Satoh; Nobuyuki Kato
Journal:  FASEB Bioadv       Date:  2021-03-04

4.  PCBP2 enhances the antiviral activity of IFN-α against HCV by stabilizing the mRNA of STAT1 and STAT2.

Authors:  Zhongshuai Xin; Wei Han; Zhiqiang Zhao; Qing Xia; Bin Yin; Jiangang Yuan; Xiaozhong Peng
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

5.  Permissiveness of human hepatoma cell lines for HCV infection.

Authors:  Bruno Sainz; Naina Barretto; Xuemei Yu; Peter Corcoran; Susan L Uprichard
Journal:  Virol J       Date:  2012-01-24       Impact factor: 4.099

Review 6.  Advancement in the development of models for hepatitis C research.

Authors:  Wendy C Carcamo; Cuong Q Nguyen
Journal:  J Biomed Biotechnol       Date:  2012-05-30

7.  New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.

Authors:  Youki Ueda; Midori Takeda; Kyoko Mori; Hiromichi Dansako; Takaji Wakita; Hye-Sook Kim; Akira Sato; Yusuke Wataya; Masanori Ikeda; Nobuyuki Kato
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

8.  Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.

Authors:  Shinya Satoh; Kyoko Mori; Youki Ueda; Hiroe Sejima; Hiromichi Dansako; Masanori Ikeda; Nobuyuki Kato
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

9.  Correlation of hepatitis C virus-mediated endoplasmic reticulum stress with autophagic flux impairment and hepatocarcinogenesis.

Authors:  Yuichi Honma; Koichiro Miyagawa; Yuichi Hara; Tsuguru Hayashi; Masashi Kusanaga; Noriyoshi Ogino; Sota Minami; Shinji Oe; Masanori Ikeda; Keisuke Hino; Masaru Harada
Journal:  Med Mol Morphol       Date:  2021-01-01       Impact factor: 2.309

10.  Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems.

Authors:  Nobuyuki Kato; Hiroe Sejima; Youki Ueda; Kyoko Mori; Shinya Satoh; Hiromichi Dansako; Masanori Ikeda
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.